ERYTECH Pharma S.A.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
ERYTECH Pharma S.A. merged with Phercydes Pharma in June 2023 to become PHAXIAM Therapeutics. As PHAXIAM, the company is a clinical-stage biopharmaceutical firm dedicated to developing innovative antibacterial treatments based on bacteriophages (phages). Its core mission is to combat antimicrobial resistance (AMR) by creating highly targeted therapies for severe bacterial infections in humans, including those caused by multi-drug resistant pathogens. The company's technology uses phages, which are viruses that specifically infect and destroy bacteria while being harmless to humans. This represents a strategic shift from ERYTECH's previous focus on developing red blood cell-based therapeutics for cancer and orphan diseases.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for ERYTECH Pharma S.A..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-18 07:00 |
Delisting Announcement
Informations privilégiées / Autres communiqués
|
French | 168.4 KB | |
| 2025-06-18 07:00 |
Delisting Announcement
Inside Information / Other news releases
|
English | 169.6 KB | |
| 2025-06-12 18:00 |
Delisting Announcement
Informations privilégiées / Autres communiqués
|
French | 173.5 KB | |
| 2025-06-12 18:00 |
Delisting Announcement
Inside Information / Other news releases
|
English | 180.8 KB | |
| 2025-06-05 07:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 116.9 KB | |
| 2025-06-05 07:00 |
Delisting Announcement
Inside Information / Other news releases
|
English | 121.1 KB | |
| 2025-05-22 18:00 |
Delisting Announcement
Inside Information / Other news releases
|
English | 118.8 KB | |
| 2025-05-22 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 116.6 KB | |
| 2025-05-05 07:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 118.8 KB | |
| 2025-05-05 07:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 118.4 KB | |
| 2025-04-24 18:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 155.0 KB | |
| 2025-04-24 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 125.4 KB | |
| 2025-03-14 17:45 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 168.3 KB | |
| 2025-03-14 17:45 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 172.5 KB | |
| 2025-03-06 17:56 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 159.2 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
